READ OUR LATEST NEWS
Recent News
June 17, 2025
35Pharma to Receive “Promising Biotech Company of the Year” Award from BIOTECanada’s 2025 Gold Leaf Awards
Montreal, QC, Canada (Jun 17, 2025) – 35Pharma, a clinical-stage biopharmaceutical company developing TGF-beta superfamily therapeutics, today announced that it has been selected to receive the 2025 Gold Leaf Award for “Promising Biotech Company of the Year” from BIOTECanada. “We are grateful to receive the Gold Leaf Award for Promising Biotech Company of the Year by BIOTECanada. This recognition […]
November 26, 2024
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
Montreal, QC, Canada (Nov 26, 2024) – 35Pharma, a clinical-stage biopharmaceutical company developing TGF-beta superfamily therapeutics, today announced the closing of an oversubscribed $53 million Series C financing. The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity. The Series C […]
November 3, 2024
35Pharma Announces Oral Presentation of HS235 Pre-Clinical Data in Obese HFpEF at ObesityWeek® 2024
Montreal, QC, Canada (Nov 03, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at ObesityWeek® 2024 in San Antonio, TX, USA (Nov 3-6, 2024). HS235 is an Fc-fused ligand trap that selectively and potently neutralizes pathological Activins and growth differentiation factors […]
October 18, 2024
35Pharma Cleared to Initiate Clinical Development of HS235, Novel Activin and GDF Inhibitor for Cardiometabolic Disease and Obesity
Montreal, QC, Canada (Oct 18, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it received a No Objection Letter from Health Canada for its Clinical Trial Application to initiate HS235-001, a Phase 1 study of HS235 in overweight and obese healthy subjects. “HS235 selectively and potently neutralizes pathological Activins and […]
June 19, 2024
35Pharma Announces Participation at Upcoming Investor Conferences
Montreal, QC, Canada (June 19, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it will be participating at the following investor conferences: Leerink Partners Private Company Connect Piper Sandler 2nd Annual Virtual Obesity Day Fireside Chat About 35Pharma 35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the […]
March 25, 2024
35Pharma Announces Oral Presentation at the 2024 American College of Cardiology Scientific Session
Montreal, QC, Canada (Mar 25, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) in Atlanta, GA, USA (April 6 – 8, 2024). The presentation will feature pre-clinical data on HS135, […]
